Trajectory of migraine-related disability following long-term treatment with lasmiditan: results of the GLADIATOR study

Table 1 Baseline characteristics by lasmiditan dose for the GLADIATOR MIDAS population

Parameter	Lasmiditan 100 mg (N = 974)	Lasmiditan 200 mg (N = 1063)
Age, mean years (SD)	42.8 (12.3)	43.6 (12.4)
Female, n (%)	828 (85.0)	904 (85.0)
Body mass index, kg/m² (SD)	31.1 (8.2)	31.0 (8.1)
Race
White, n (%)	744 (76.4)	837 (78.7)
African American, n (%)	193 (19.8)	181 (17.0)
Other, n (%)	37 (3.8)	43 (4.0)
Duration of migraine, mean years (SD)	18.8 (12.8)	18.8 (12.9)
Migraine attacks/month, mean n (SD)^a	5.2 (1.8)	5.2 (1.8)
Migraine with aura^b,c, n (%)	356 (36.6)	366 (34.5)
Migraine preventive medication use, n (%)	214 (22.0)	234 (22.0)
Patients with CV risk factors^b,d, n (%)
≥ 1	814 (83.6)	852 (80.2)
≥ 2	482 (49.5)	519 (48.8)
MIDAS questionnaire
MIDAS total score^e, mean (IQR)	29.4 (15, 36)	28.9 (15, 35)
Headache days in past 3 months, mean (IQR)^f	15.5 (8, 20)	15.5 (8, 20)
Severity of headache pain^g, mean (IQR)	7.4 (7, 8)	7.3 (6, 8)

Abbreviations: CAD coronary artery disease; CV cardiovascular; IQR interquartile range; MIDAS Migraine Disability Assessment; SD standard deviation
^aBased on response to the question in migraine history section of the case report form “Frequency of migraine attacks (average) during the last three months.” ^bData from parent study. ^cFulfilling ICHD criteria 1.2.1 for migraine with typical aura. ^dHypertension, hypercholesterolemia, smoking, obesity, diabetes mellitus, family history of CAD, men over 40 years of age, and postmenopausal women. ^eCalculated as the sum of the answers to the 5 questions on the MIDAS questionnaire (0–5 = little or no disability; 6–10 = mild disability; 11–20 = moderate disability; ≥21 = severe disability; >40 = very severe disability). ^f“On how many days in the past 3 months did you have a headache? (If a headache lasted more than 1 day, count each day)”. ^g“On a scale of 0 to 10, on average how painful were these headaches? (where 0 = no pain at all, and 10 = pain as bad as it can be)”

ISSN: 1129-2377